公开(公告)号：US20210146047A1

公开(公告)日：2021-05-20

申请号：US16687481

申请日：2019-11-18

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Guangping Zhang ,  Kiem H. Dang ,  Valerie Chen ,  Ling Jiang ,  Evan Anselmo ,  Zhiwu Fang ,  Sarnath Chattaraj

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/14 ,  A61M5/168

Abstract: Disclosed herein are combined devices and methods of manufacturing such combined devices. The combined devices disclosed herein include an analyte sensor including a sensor probe; an infusion set hub including a cannula; and a flexible base. The analyte sensor and infusion set hub are attached to the flexible base such that movement of one of the analyte sensor and the infusion set hub is substantially not transferred to the other one of the analyte sensor and the infusion set hub.

公开(公告)号：US20200230318A1

公开(公告)日：2020-07-23

申请号：US16839654

申请日：2020-04-03

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Guangping Zhang ,  Sarnath Chattaraj ,  Anuradha Biswas Bhatia ,  Maria C. LoVerme ,  Afshin Bazargan

IPC: A61M5/172 ,  G01N21/3577 ,  A61M39/20

Abstract: Medical devices and methods and apparatuses for identifying fluids in a conduit of a device are provided. An exemplary medical device includes a reservoir for holding a fluid and a conduit for dispensing the fluid from the reservoir. Further, the medical device includes a spectroscopy device for examining the fluid.

公开(公告)号：US20190223771A1

公开(公告)日：2019-07-25

申请号：US15878313

申请日：2018-01-23

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Jia Yao ,  Daniel E. Pesantez ,  Anuradha Biswas Bhatia ,  Akhil Srinivasan ,  Guangping Zhang ,  Andrea Varsavsky ,  Raghavendhar Gautham

IPC: A61B5/1486 ,  A61L31/04 ,  A61L31/14 ,  C12Q1/00 ,  C12Q1/54 ,  C12Q1/26 ,  A61B5/145

Abstract: Embodiments of the invention provide optimized polymeric surfaces adapted for use with implantable medical devices as well as methods for making and using such polymeric surfaces. These polymer surfaces have a constellation of features that function to inhibit or avoid an inflammatory immune response generated by implantable medical devices. Typical embodiments of the invention include an implantable glucose sensor used in the management of diabetes having a polymer surface with the disclosed constellation of features.

公开(公告)号：US20190216397A1

公开(公告)日：2019-07-18

申请号：US16248623

申请日：2019-01-15

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Matthew William Yavorsky ,  Sarnath Chattaraj ,  Kiem H. Dang ,  Guangping Zhang

IPC: A61B5/00 ,  A61B5/145 ,  A61B5/1486 ,  A61M5/158

CPC classification number: A61B5/6833 ,  A61B5/14532 ,  A61B5/1486 ,  A61M5/158 ,  A61M2005/1586

Abstract: A medical device includes a hub and an adhesive patch coupled to the hub. The adhesive patch is to couple the hub to an anatomy. The adhesive patch defines an edge that extends along a perimeter of the adhesive patch. The medical device includes an anisotropic shim coupled to the adhesive patch along the perimeter of the adhesive patch proximate the edge to resist an uncoupling of the adhesive patch from the anatomy. The shim has an inner periphery spaced apart from an outer periphery and the shim is locally rigid between the inner periphery and the outer periphery.

公开(公告)号：US20250108150A1

公开(公告)日：2025-04-03

申请号：US18981099

申请日：2024-12-13

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US12201752B2

公开(公告)日：2025-01-21

申请号：US17499612

申请日：2021-10-12

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US12042284B2

公开(公告)日：2024-07-23

申请号：US15878313

申请日：2018-01-23

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Jia Yao ,  Daniel E. Pesantez ,  Anuradha Biswas Bhatia ,  Akhil Srinivasan ,  Guangping Zhang ,  Andrea Varsavsky ,  Raghavendhar Gautham

IPC: A61B5/1486 ,  A61B5/145 ,  A61L31/04 ,  A61L31/14 ,  C09D5/16 ,  C12Q1/00 ,  C12Q1/26 ,  C12Q1/54 ,  A61B5/00

CPC classification number: A61B5/14865 ,  A61B5/1451 ,  A61B5/14532 ,  A61L31/04 ,  A61L31/14 ,  C09D5/1681 ,  C12Q1/006 ,  C12Q1/26 ,  C12Q1/54 ,  A61B5/41 ,  A61L2400/18

Abstract: Embodiments of the invention provide optimized polymeric surfaces adapted for use with implantable medical devices as well as methods for making and using such polymeric surfaces. These polymer surfaces have a constellation of features that function to inhibit or avoid an inflammatory immune response generated by implantable medical devices. Typical embodiments of the invention include an implantable glucose sensor used in the management of diabetes having a polymer surface with the disclosed constellation of features.

公开(公告)号：US11944784B2

公开(公告)日：2024-04-02

申请号：US16687481

申请日：2019-11-18

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Guangping Zhang ,  Kiem H. Dang ,  Valerie Chen ,  Ling Jiang ,  Evan Anselmo ,  Zhiwu Fang ,  Sarnath Chattaraj

IPC: A61M5/172 ,  A61B5/145 ,  A61M5/14 ,  A61M5/142 ,  A61M5/168

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/1413 ,  A61M5/14248 ,  A61M5/16836

Abstract: Disclosed herein are combined devices and methods of manufacturing such combined devices. The combined devices disclosed herein include an analyte sensor including a sensor probe; an infusion set hub including a cannula; and a flexible base. The analyte sensor and infusion set hub are attached to the flexible base such that movement of one of the analyte sensor and the infusion set hub is substantially not transferred to the other one of the analyte sensor and the infusion set hub.

公开(公告)号：US20220409777A1

公开(公告)日：2022-12-29

申请号：US17823388

申请日：2022-08-30

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/38 ,  A61K9/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US20220031941A1

公开(公告)日：2022-02-03

申请号：US17499612

申请日：2021-10-12

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61M5/168 ,  A61M5/142 ,  A61M5/162

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.